AVAILABLENot Applicable

Individual Patient Compassionate Use of Mirdametinib

Plain-language summary

This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.

Who can participate

Age range2 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient has a serious, debilitating or life-threatening medical condition that cannot be treated satisfactorily with an authorized medicinal product or other available standard treatment options, or all other treatment options have been exhausted. * Patient does not qualify to participate in an ongoing clinical trial.

Trial details

NCT IDNCT05028166

SponsorSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Sponsor typeINDUSTRY

Study typeEXPANDED_ACCESS

Contact for this trial

US Medical Information

888-275-7376 eMediUSA@emdserono.com

View on ClinicalTrials.gov More Neurofibromatosis Type 1-Associated Plexiform Neurofibromas trials